2024
Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related quality
2023
Aiming for the cure in myeloma: Putting our best foot forward
Bar N, Firestone R, Usmani S. Aiming for the cure in myeloma: Putting our best foot forward. Blood Reviews 2023, 62: 101116. PMID: 37596172, DOI: 10.1016/j.blre.2023.101116.Peer-Reviewed Original ResearchConceptsMultiple myelomaMinimal residual disease negativityDeeper response ratesResponse-adapted strategyDuration of therapyPowerful prognostic factorSignificant inter-patient variabilityNovel clinical trialsInter-patient variabilityRegimen compositionFrontline therapyUpfront therapyPrognostic factorsMyeloma patientsMyeloma treatmentClinical trialsTreatment strategiesCurrent relevant literatureTreatment approachesResponse rateDisease riskTherapyMyelomaUse of transplantsCurrent standard